EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comprehensive benchmarking of EEG biomarkers for Parkinson's disease: robustness, reliability, and clinical discriminability across multiple datasets

Sepideh Hajipour Sardouie iD, Mahsa Naseri iD, Mahdi Babaei iD, Zahra Kavian iD, Shervin Mehrtash, Mohamad Hosein Faramarzi, Maryam S Mirian, Martin James McKeown iD

Journal of Neural Engineering · 05.11.2026

DOI: 10.1088/1741-2552/aebe69 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neural Engineering, online erschienen am 05.11.2026. Verfasst von Sepideh Hajipour Sardouie und 7 weiteren Autor:innen. Beteiligte Einrichtung: UBC, Pacific Parkinson's Research Centre, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, V6…. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institute for Health Research, the John Nichol Chair in Parkinson’s Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Electroencephalography (EEG) provides a high-temporal-resolution, noninvasive window into some of the abnormalities underlying Parkinson’s disease (PD), yet reported electrophysiological biomarkers vary widely across studies due to differences in preprocessing, feature extraction, and analytical pipelines. Here we provide the first comprehensive, multi-dataset benchmarking of 16 EEG-derived biomarkers, including phase-amplitude coupling, beta burst metrics, aperiodic components, complexity measures, and beta waveform features, to evaluate their robustness, reliability, and clinical discriminability. Using three independent resting-state EEG datasets, with two preprocessing conditions evaluated for one dataset, we assessed the effects of preprocessing, window length, within-session variability, channel aggregation strategies, and clinical group differences (healthy controls vs. PD OFF-medication, healthy controls vs. PD ON-medication, and PD OFF- vs. ON-medication). Cross-dataset reproducibility of group-level effects was additionally evaluated using effect-size pattern similarity, biomarker rank concordance, effect-direction consistency, and random-effects meta-analysis. 
Aperiodic features, entropy and complexity measures, and fractal metrics demonstrated high methodological robustness across preprocessing methods, window lengths, and aggregation strategies, and several showed disease- and medication-related effects across datasets, although effect magnitude and statistical significance varied across datasets and analytical conditions. In contrast, oscillatory biomarkers, including beta-gamma phase-amplitude coupling, burst-derived metrics, and waveform-asymmetry features, showed substantial variability across methodological choices and lower within-session consistency. However, this methodological sensitivity should not necessarily be interpreted as lower biological relevance, as these measures may capture more transient or state-dependent physiological dynamics. Fully-denoised data improved group-level separability, for several biomarkers in Dataset 1. Together, these findings identify several biomarkers with comparatively strong methodological robustness for further biological and clinical validation and highlight methodological factors that contribute to inconsistencies in the PD literature. This benchmarking framework provides practical guidance for standardizing biomarker analysis while emphasizing that methodological robustness, biological sensitivity, and clinical utility represent distinct dimensions of biomarker performance.

Schlagwörter

Stichwörter der Autor:innen

Aperiodic activityBeta oscillationsEEGElectrophysiological biomarkersParkinson's diseasePhase-amplitude couplingSignal complexity

Autor:innen und Institutionen

  • UBC, Pacific Parkinson's Research Centre, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, V6T 1Z4, Canada.
  • UBC, Pacific Parkinson's Research Centre, Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, V6T 1Z4, Canada.
  • The University of British Columbia - Vancouver Campus, Pacific Parkinson's Research Centre, Djavad Mowafaghian Centre for Brain Health, Vancouver, V6T 1Z4, Canada.

ORCID-Profile: Sepideh Hajipour Sardouie, Mahsa Naseri, Mahdi Babaei, Zahra Kavian, Martin James McKeown

Förderung

  • Canadian Institute for Health Research
  • the John Nichol Chair in Parkinson’s Research

Zitieren

APA

Hajipour Sardouie, S., Naseri, M., Babaei, M., Kavian, Z., Mehrtash, S., Faramarzi, M. H., Mirian, M. S., & McKeown, M. J. (2026). Comprehensive benchmarking of EEG biomarkers for Parkinson's disease: robustness, reliability, and clinical discriminability across multiple datasets. Journal of Neural Engineering. https://doi.org/10.1088/1741-2552/aebe69

Vancouver

Hajipour Sardouie S, Naseri M, Babaei M, Kavian Z, Mehrtash S, Faramarzi MH, et al. Comprehensive benchmarking of EEG biomarkers for Parkinson's disease: robustness, reliability, and clinical discriminability across multiple datasets. Journal of Neural Engineering. 2026. doi:10.1088/1741-2552/aebe69

BibTeX
@article{HajipourSardouie2026,
  author = {Hajipour Sardouie, Sepideh and Naseri, Mahsa and Babaei, Mahdi and Kavian, Zahra and Mehrtash, Shervin and Faramarzi, Mohamad Hosein and Mirian, Maryam S and McKeown, Martin James},
  title = {Comprehensive benchmarking of EEG biomarkers for Parkinson's disease: robustness, reliability, and clinical discriminability across multiple datasets},
  journal = {Journal of Neural Engineering},
  year = {2026},
  doi = {10.1088/1741-2552/aebe69}
}
Kostenlos starten →